par Caparica Bitton, Rafael 
;Richard, François;Brandao, Marianna;Awada, Ahmad ;Sotiriou, Christos ;de Azambuja, Evandro
Référence Clinical breast cancer
Publication Publié, 2020-01-01
;Richard, François;Brandao, Marianna;Awada, Ahmad ;Sotiriou, Christos ;de Azambuja, Evandro Référence Clinical breast cancer
Publication Publié, 2020-01-01
Article révisé par les pairs
| Résumé : | ADRB2 mediates trastuzumab resistance in preclinical models of HER2+ breast cancer. We evaluated ADRB2 gene expression as a prognostic and predictive biomarker in HER2+ early breast cancer patients. Opposing our initial hypothesis, a high ADRB2 expression may exert antiproliferative, antiangiogenic, and immunogenic effects, and thus be associated with a favorable prognosis in patients with HER2+ early breast cancer. |
